Efficacy and tolerability of Casodex in patients with advanced prostate cancer. International Casodex Study Group.
The efficacy and tolerability of Casodex, a new non-steroidal antiandrogen, were studied in 267 patients with advanced prostate cancer. All patients received Casodex, 50 mg daily, as monotherapy. The objective response rate was 55.5% and the subjective response rate was 56.1%. The most common adverse events were the expected pharmacological effects of breast tenderness, gynecomastia and hot flushes. No other adverse events were reported in more than 5% of patients. There was minimal occurrence of impotence, loss of libido and diarrhea. The results show that Casodex 50 mg is effective and well tolerated in the treatment of advanced prostate cancer.
Lunglmayr
G
G
Hospital Mistelbach, Austria.
D000368:Aged; D000369:Aged, 80 and over; D000813:Anilides / Q000009:adverse effects / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D004562:Electrocardiography; D005060:Europe; D006801:Humans; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D010146:Pain / Q000209:etiology; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D013739:Testosterone / Q000097:blood; D014105:Tosyl Compounds
D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014105:Tosyl Compounds; D013739:Testosterone; C053541:bicalutamide